Sage Therapeutics' SAGE-217, which is being assessed in a late-stage study for the treatment of patients with major depressive disorder, was granted breakthrough therapy status by the FDA.
Sage's major depressive disorder drug given FDA breakthrough status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.